Bordin J O, Souza-Pinto J C, Kerbauy J
Disciplina de Hematologia e Hemoterapia, Escola Paulista de Medicina, São Paulo, Brasil.
Braz J Med Biol Res. 1991;24(9):895-9.
The enzyme-linked antiglobulin test (ELAT) was employed to measure the number of IgG molecules per red blood cell (IgG/RBC) in 11 patients with autoimmune hemolytic anemia (AIHA). All patients with AIHA had high levels of red cell-associated IgG (110-3, 650 IgG/RBC). The control group consisted of normal volunteers (N = 10) and patients with hereditary spherocytosis (N = 1), beta 0-thalassemia (N = 1), immunologic thrombocytopenic purpura (N = 3) and IgG multiple myeloma (N = 4). All control individuals presented low levels of red cell IgG (less than 38 IgG/RBC) with the exception of one of four patients with myeloma who had a mildly elevated value (50 IgG/RBC). Since the multiple myeloma patients had greater than 2 g/dl IgG, the possible nonspecific uptake of IgG onto the RBCs of patients with elevated serum IgG values did not interfere with the results of ELAT. ELAT proved to be a useful method for accurate quantification of the amount of IgG specifically bound on the surface of RBC of patients with AIHA.
采用酶联抗球蛋白试验(ELAT)检测11例自身免疫性溶血性贫血(AIHA)患者每红细胞(IgG/RBC)的IgG分子数。所有AIHA患者的红细胞相关IgG水平均较高(110 - 3650 IgG/RBC)。对照组包括正常志愿者(N = 10)、遗传性球形红细胞增多症患者(N = 1)、β0地中海贫血患者(N = 1)、免疫性血小板减少性紫癜患者(N = 3)和IgG多发性骨髓瘤患者(N = 4)。除4例骨髓瘤患者中有1例值轻度升高(50 IgG/RBC)外,所有对照个体的红细胞IgG水平均较低(低于38 IgG/RBC)。由于多发性骨髓瘤患者的IgG大于2 g/dl,血清IgG值升高患者的红细胞上IgG可能的非特异性摄取并未干扰ELAT结果。ELAT被证明是一种准确量化AIHA患者红细胞表面特异性结合IgG量的有用方法。